Attached files

file filename
EX-16.1 - EX-16.1 - Bionovate Technologies Corp.ex_161.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 5, 2018

 

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

333-188152

33-1229553

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

3651 Lindell Road, Suite D1141, Las Vegas, NV

 

89103

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (208) 231-1606

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 
 
 
 

Item 4.01

Changes in Registrant's Certifying Accountant

 

Previous independent registered public accounting firm

 

a) On April 5, 2018, we dismissed MNP LLP ("MNP") as our company’s independent principal accountant to audit our company’s financial statements. The decision to change accountants was approved by our board of directors. Our company does not have a standing Audit Committee.

 

Our company's independent principal accountant's report on the financial statements for each of the past two years did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, with the exception that:

 

(i) the report dated September 16, 2016 contained the following explanatory paragraph: As discussed in Note 1 to the consolidated financial statements, the Corporation has accumulated losses of $280,133 since its inception. These conditions raise substantial doubt about the Corporation’s ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."; and

 

(ii) the report dated September 17, 2015 contained the following explanatory paragraph: " As discussed in Note 1 to the consolidated financial statements, the Corporation has accumulated losses of $230,127 since its inception. These conditions raise substantial doubt about the Corporation’s ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

 

During our company’s two most recent fiscal years and the subsequent interim periods preceding our dismissal of MNP, there were: (i) no disagreements with MNP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of MNP, would have caused it to make reference to the subject matter of the disagreements in its reports on the consolidated financial statements of the Company; and (ii) no reportable events as described in Item 304(a)(1)(v) of Regulation S-K.

 

We have provided MNP with a copy of this Form 8-K prior to its filing with the U.S. Securities and Exchange Commission ("SEC") and requested MNP to furnish to our company a letter addressed to the SEC stating that it agrees with the statements made above. A copy of MNP's letter is attached as Exhibit 16.1 to this Form 8-K.

 

New independent registered public accounting firm

 

b) On April 5, 2018, we engaged BF Borgers CPA PC ("Borgers"), an independent certified public accounting firm, as our principal independent accountant with the approval of our board of directors.

 

During the two most recent fiscal years and through the date of engagement, we have not consulted with Borgers regarding either:

 

1. The application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements, and neither a written report was provided to us nor oral advice was provided that Borgers concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issue; or

 

2. Any matter that was either subject of disagreement or event, as defined in Item 304(a)(1)(iv)(A) of Regulation S-K and the related instruction to Item 304 of Regulation S-K, or a reportable event, as that term is explained in Item 304(a)(1)(iv)(A) of Regulation S-K.

 

Item 9.01

 

Financial Statements and Exhibits

16.1

 

Letter from MNP LLP

 

 
2
 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BIONOVATE TECHNOLOGIES CORP.

 

 

 

 

 

/s/ Liao Zu Guo

 

Liao Zu Guo

 

Chief Executive Officer

 

 

 

Date:

April 5, 2018

 

 

 

3